ProQR Therapeutics NV (MEX:PRQRN) Selling, General, & Admin. Expense: MXN328.3 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
50 GF Score
Price MXN36.00
GF Value MXN37.10
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Selling, General, & Admin. Expense?

ProQR Therapeutics NV MEX:PRQRN 50 Selling, General, & Admin. Expense is MXN328.3 Mil as of Jun. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 50/100 and a GF Value™ of MXN37.10. The stock has 2 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. ProQR Therapeutics NV's selling, general, & admin. expense for the three months ended in Jun. 2026 was MXN98.8 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN328.3 Mil.


ProQR Therapeutics NV  (MEX:PRQRN) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


ProQR Therapeutics NV Selling, General, & Admin. Expense Related Terms


ProQR Therapeutics NV Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Selling, General, & Admin. Expense Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 402.58 385.19 300.54 298.34 317.52

ProQR Therapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.59 67.15 82.04 80.30 98.78

MEX:PRQRN vs NWBO, IMRX, VNDA: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, ProQR Therapeutics NV's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProQR Therapeutics NV Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProQR Therapeutics NV's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where ProQR Therapeutics NV's Selling, General, & Admin. Expense falls into.


MEX:PRQRN
50GF Score
ProQR Therapeutics NV MEX:PRQRN
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN328.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of MXN328.3 Mil mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Selling, General, & Admin. Expense of MXN328.3 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Selling, General, & Admin. Expense too high?
ProQR Therapeutics NV's current Selling, General, & Admin. Expense is MXN328.3 Mil. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Selling, General, & Admin. Expense compare to NWBO and IMRX?
ProQR Therapeutics NV's Selling, General, & Admin. Expense of MXN328.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Selling, General, & Admin. Expense is MXN328.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Selling, General, & Admin. Expense of MXN328.3 Mil. The stock's GF Value™ is MXN37.10, compared to a current price of MXN36.00 — trading 3% below its estimated fair value. The current Selling, General, & Admin. Expense is MXN328.3 Mil. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Selling, General, & Admin. Expense is MXN328.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 3% below its estimated GF Value™ of MXN37.10.

Key valuation signals for MEX:PRQRN:

  • Selling, General, & Admin. Expense: MXN328.3 Mil
  • GF Value™: MXN37.10 vs. price of MXN36.00 (3% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for MEX:PRQRN

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN37.10
GF Value